Published in Lab Business Week, July 3rd, 2005
In the 3-month period ended March 31, 2005, the company incurred research and development expenses of $3,105, a decrease of $125,265 from the $128,370 incurred in the 3-month period March 31, 2004. Expenses in the first quarter were lower than in the previous quarter as the company completed its phase II clinical trial and reports relating to the scientific development of DCF 987 in 2004.
These expenditures are expected to remain at a minimum level as future development of DCF 987 will be undertaken by Align Pharmaceuticals, Inc., (ALIGN). Government assistance...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week